EUVIMEDEUVIMED entdecken
Open Access

Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice

Eirini Papadopoulou iD, George Rigas, Elena Fountzilas iD, Anastasios Boutis, Stylianos Giassas, Nikolaos Mitsimponas, Danai Daliani iD, Dimitrios C Ziogas, Michalis Liontos iD, Vasileios Ramfidis, Charalampos Christophilakis, Dimitris Matthaios und 10 weitere

JCO Precision Oncology · 2024

DOI: 10.1200/po.23.00332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Eirini Papadopoulou und 21 weiteren Autor:innen. Beteiligte Einrichtung: Genekor Medical SA, Athens, Greece. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms, Endometrial Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The pan-cancer presence of microsatellite instability (MSI)–positive tumors demonstrates its clinical utility as an agnostic biomarker for identifying immunotherapy-eligible patients. Additionally, MSI is a hallmark of Lynch syndrome (LS), the most prevalent cancer susceptibility syndrome among patients with colorectal and endometrial cancer. Therefore, MSI-high results should inform germline genetic testing for cancer-predisposing genes. However, in clinical practice, such analysis is frequently disregarded. METHODS A next-generation sequencing (NGS)–based technique was used for MSI analysis in 4,553 patients with various tumor types. Upon request, somatic BRAF gene analysis was conducted. In addition, hereditary testing of cancer-associated genes was performed in MSI-high cases using a capture-based NGS protocol. MLH1 promoter methylation analysis was conducted retrospectively in patients with colorectal and endometrial cancer to further investigate the origin of MSI at the tumor level. RESULTS The MSI positivity rate for the entire cohort was 5.27%. Endometrial, gastric, colorectal, urinary tract, and prostate cancers showed the highest proportion of MSI-high cases (15.69%, 8.54%, 7.40%, 4.55%, and 3.19%, respectively). A minority of 45 patients (22.73%) among the MSI-high cases underwent germline testing to determine whether the mismatch repair pathway deficiency was inherited. 24.44% of those who performed the genetic test carried a pathogenic variant in an LS-associated gene. Three MSI-high individuals had non-LS gene alterations, including BRCA1, BRCA2, and CDKN2A pathogenic variants, indicating the presence of non–LS-associated gene alterations among MSI-high patients. CONCLUSION Although MSI analysis is routinely performed in clinical practice, as many as 77% of MSI-high patients do not undergo LS genetic testing, despite international guidelines strongly recommending it. BRAF and MLH1 methylation analysis could shed light on the somatic origin of MSI in 42.50% of the MSI-high patients; however, MLH1 analysis is barely ever requested in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal Neoplasms, Hereditary NonpolyposisColorectal NeoplasmsEndometrial NeoplasmsBrain NeoplasmsNeoplastic Syndromes, HereditaryMaleFemaleHumansRetrospective StudiesMicrosatellite InstabilityProto-Oncogene Proteins B-rafBiomarkers

Substanzen

Proto-Oncogene Proteins B-rafBiomarkers

Autor:innen und Institutionen

  • Genekor Medical SA, Athens, Greece.
  • Medical Oncology Unit, General Hospital of Volos, Volos, Greece.
  • Second Department of Medical Oncology, Euromedica General Clinic, Thessaloniki, Greece.
  • First Department of Clinical Oncology, Theagenio Hospital, Thessaloniki, Greece.
  • Second Oncology Clinic IASO, General Maternity and Gynecology Clinic, Athens, Greece.
  • First Oncology Clinic Hygeia Hospital, Athens, Greece.

ORCID-Profile: Eirini Papadopoulou, Elena Fountzilas, Danai Daliani, Michalis Liontos, Anastasia Katseli, Georgios Tsaousis

Zitieren

APA

Papadopoulou, E., Rigas, G., Fountzilas, E., Boutis, A., Giassas, S., Mitsimponas, N., Daliani, D., Ziogas, D. C., Liontos, M., Ramfidis, V., Christophilakis, C., Matthaios, D., Floros, T., Florou-Chatzigiannidou, C., Agiannitopoulos, K., Meintani, A., Tsantikidi, A., Katseli, A., Potska, K., …, & Nasioulas, G. (2024). Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice. JCO Precision Oncology. https://doi.org/10.1200/po.23.00332

Vancouver

Papadopoulou E, Rigas G, Fountzilas E, Boutis A, Giassas S, Mitsimponas N, et al. Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice. JCO Precision Oncology. 2024. doi:10.1200/po.23.00332

BibTeX
@article{Papadopoulou2024,
  author = {Papadopoulou, Eirini and Rigas, George and Fountzilas, Elena and Boutis, Anastasios and Giassas, Stylianos and Mitsimponas, Nikolaos and Daliani, Danai and Ziogas, Dimitrios C and Liontos, Michalis and Ramfidis, Vasileios and Christophilakis, Charalampos and Matthaios, Dimitris and Floros, Theofanis and Florou-Chatzigiannidou, Chrysiida and Agiannitopoulos, Konstantinos and Meintani, Angeliki and Tsantikidi, Aikaterini and Katseli, Anastasia and Potska, Kevisa and Tsaousis, Georgios and Metaxa-Mariatou, Vasiliki and Nasioulas, George},
  title = {Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.23.00332}
}
Kostenlos starten →